1 February 2009: Following the closing of the subscription period of NorDiag's rights issue Friday 30 January 2009, the Board of NorDiag has approved the allotment of the new shares. The following primary insiders and related parties of such have subscribed and been allotted new shares and warrants in the share issue:

- Chairman of the Board Hans Hekland: Hannibal Invest AS (private investment company) 400,000 shares, 240,000 Class A Warrants and 240,000 Class B Warrants. Total new holdings:  502 801 shares, 240,000 Class A Warrants and 240,000 Class B Warrants. Sarsia Innovation AS (Hans Hekland CEO) 1,000,000 shares, 600,000 Class A Warrants and 600,000 Class B Warrants.  Total new holdings: 1,579,000 shares, 600,000 Class A Warrants and 600,000 Class B Warrants. Sarsia Life Science Fund AS (Hans Hekland CEO) 20,000,000 shares, 12,000,000 Class A Warrants and 12,000,000 Class B Warrants. Total new holdings: 32,985,381 shares 12,000,000 Class A Warrants and 12,000,000 Class B Warrants.

- Newly elected Chairman of the Board Robert V. Ahlgren: 300,000 shares, 180,000 Class A Warrants and 180,000 Class B Warrants. Total new holdings: 300,000 shares, 180,000 Class A Warrants and 180,000Class B Warrants.

- CFO Tone Kvåle 112,500 shares, 56,250 Class A Warrants and 56,250 Class B Warrants. Total new holdings: 162,500 shares, 56,250 Class A Warrants and 56,250 Class B Warrants. Tone Kvåle holds in addition 300,000 share options prior to completion of the share issue.

- Medical Director Dagfinn Øgreid: Colon AS (private investment company) 1,000,000 shares, 500,000 Class A Warrants and 500,000 Class B Warrants. Total new holdings: 2,464,172 shares, 500,000 Class A Warrants and 500,000 Class B Warrants.

- Chief Accountant Stein Rune Kjelby: 60,000 shares, 30,000 Class A Warrants and 30,000 Class B Warrants. Total new holdings: 60 000 shares, 30,000 Class A Warrants and 30,000 Class B Warrants. Stein Rune Kjelby holds in addition  54 514 share options prior to completion of the share issue.

Contact:              
CEO Mårten Wigstøl
Phone: +47 911 65775 or
                           
CFO Tone Kvåle                               
Phone: +47 915 19576

About NorDiag:
NorDiag is a biotechnology company developing, manufacturing and marketing of automated solutions, instruments and tests, for diagnostic of infectious diseases and cancer. The company`s core competence is isolation of bacterial and human DNA from difficult clinical samples, and the company has established a solid market share in the Scandinavian market for sexually transmitted infections. The company has similar applications for Tuberculosis and MRSA. An application for respiratory pathogens is under development. NorDiag is also developing a test that shall contribute to early diagnosis of colorectal cancer, as well as a test that shall contribute to optimal treatment of lung cancer patients. NorDiag was founded in 2003 and has its headquarters in Oslo - Norway. The company has also offices and laboratories in Bergen - Norway, Stockholm - Sweden and West Chester (PA) - USA. The group has 39 employees. NorDiag is listed on Oslo Stock Exchange with the ticker NORD. For further information, please see www.nordig.com.

Read the notice in Norwegian here